Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Sutro Biopharma, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 114 | 117 | +3 |
| Shares | 55.6M | 53.4M | −2.24M (−4.0%) |
| Value | $238.7M | $301.7M | +$63.0M (+26.4%) |
New holders (20)
Institutions that held Sutro Biopharma, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| MPM Oncology Impact Management LP | 4,096,619 | $23.1M | 3.72% |
| D. E. Shaw & Co., Inc. | 241,643 | $1.37M | 0.00% |
| Susquehanna Fundamental Investments, LLC | 126,459 | $714.5K | 0.03% |
| Jump Financial, LLC | 111,197 | $628.3K | 0.02% |
| EntryPoint Capital, LLC | 69,678 | $393.7K | 0.35% |
| Lighthouse Investment Partners, LLC | 66,585 | $376.2K | 0.02% |
| Chase Investment Counsel Corp | 57,700 | $326.0K | 0.12% |
| Mirae Asset Global Investments Co., Ltd. | 44,019 | $202.5K | 0.00% |
| Algert Global LLC | 23,761 | $134.3K | 0.01% |
| Two Sigma Securities, LLC | 23,291 | $131.6K | 0.01% |
| Pathstone Holdings, LLC | 22,813 | $128.9K | 0.00% |
| US Bancorp | 17,000 | $96.0K | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 16,925 | $95.6K | 0.00% |
| Lazard Asset Management LLC | 16,386 | $92.0K | 0.00% |
| STRS Ohio | 15,000 | $84.0K | 0.00% |
| HRT Financial LP | 12,057 | $68.0K | 0.00% |
| ProShare Advisors LLC | 10,943 | $61.8K | 0.00% |
| AdvisorNet Financial, Inc | 500 | $2.83K | 0.00% |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 13 | $73 | 0.00% |
| CWM, LLC | 47 | $0 | 0.00% |
Sold out (17)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| BVF Inc | 3,347,946 | $14.4M |
| Rubric Capital Management LP | 3,344,810 | $14.3M |
| Franklin Resources Inc | 2,762,636 | $11.9M |
| Sectoral Asset Management Inc | 623,684 | $2.68M |
| Pentwater Capital Management LP | 450,000 | $1.93M |
| Opaleye Management Inc. | 301,491 | $1.29M |
| Exome Asset Management LLC | 153,600 | $658.9K |
| Walleye Capital LLC | 73,271 | $314.3K |
| Aristides Capital LLC | 50,476 | $216.5K |
| State of Wisconsin Investment Board | 30,400 | $130.4K |
| Susquehanna Portfolio Strategies, LLC | 26,668 | $114.4K |
| Squarepoint Ops LLC | 13,903 | $59.6K |
| Virtus Fund Advisers, LLC | 4,412 | $18.9K |
| Point72 Middle East FZE | 1,798 | $7.71K |
| Cape Investment Advisory, Inc. | 1,000 | $4.29K |
| Federated Hermes, Inc. | 223 | $957 |
| Washington Trust Advisors, Inc. | 179 | $768 |